Study summary
Adding immunotherapy to chemoradiation extended survival for high-risk cervical cancer
82.6%alive at 3 years with pembrolizumab
What was tested
Pembrolizumab added to chemoradiation and then continued, against chemoradiation with placebo, for newly diagnosed high-risk locally advanced cervical cancer.
What they found
- 36-month survival was 82.6% with pembrolizumab, and the risk of death was 33% lower (hazard ratio 0.67).
- Immune-related side effects were more common (39% vs 17%).
What it means
The first immunotherapy to improve survival when combined with chemoradiation for cervical cancer.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.